You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia
|
|---|---|
| Published in |
Journal of Hematology & Oncology, August 2017
|
| DOI | 10.1186/s13045-017-0516-x |
| Pubmed ID | |
| Authors |
Guoqing Wei, Jiasheng Wang, He Huang, Yanmin Zhao |
| Abstract |
The past decade witnessed the rapid development of adult B-lineage acute lymphoblastic leukemia (ALL) treatment. Beyond the development of chemotherapy regimens, immunotherapy is starting a new era with unprecedented complete remission (CR) rate. Targeting B-lineage-specific surface markers such as CD19, CD20, CD22, or CD52, immunotherapy has been demonstrating promising clinical results. Among the immunotherapeutic methods, naked monoclonal antibodies (mAbs), antibody-drug conjugate (ADC), bispecific T cell engager (BiTE), and chimeric antigen receptor (CAR) T cells are the main types. In this review, we will examine the emerging preclinical and clinical development on (1) anti-CD20 naked mAbs rituximab, ofatumumab, and obinutuzumab; (2) anti-CD19 ADCs SAR3419 and SGN-CD19A and anti-CD19 BiTE blinatumomab; (3) anti-CD22 naked mAb epratuzumab and anti-CD22 ADC inotuzumab ozogamicin; (4) anti-CD52 naked mAb alemtuzumab; and (5) anti-CD19 CAR T cells. We will discuss their efficacy, adverse effects, as well as future development. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 3 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 103 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 103 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 18 | 17% |
| Student > Bachelor | 16 | 16% |
| Researcher | 13 | 13% |
| Student > Master | 11 | 11% |
| Student > Doctoral Student | 7 | 7% |
| Other | 19 | 18% |
| Unknown | 19 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 32 | 31% |
| Biochemistry, Genetics and Molecular Biology | 19 | 18% |
| Immunology and Microbiology | 10 | 10% |
| Agricultural and Biological Sciences | 6 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 5% |
| Other | 12 | 12% |
| Unknown | 19 | 18% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 February 2021.
All research outputs
#6,350,245
of 22,999,744 outputs
Outputs from Journal of Hematology & Oncology
#443
of 1,198 outputs
Outputs of similar age
#101,405
of 318,830 outputs
Outputs of similar age from Journal of Hematology & Oncology
#11
of 18 outputs
Altmetric has tracked 22,999,744 research outputs across all sources so far. This one has received more attention than most of these and is in the 72nd percentile.
So far Altmetric has tracked 1,198 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.0. This one has gotten more attention than average, scoring higher than 62% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 318,830 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.
We're also able to compare this research output to 18 others from the same source and published within six weeks on either side of this one. This one is in the 38th percentile – i.e., 38% of its contemporaries scored the same or lower than it.